BRPI0511667A - combinação, produto, kit de partes, embalagem, usos de um antagonista de receptores muscarìnicos m3, e de um corticosteróide, e, método de tratar um paciente humano ou animal sofrendo de ou suscetìvel a uma doença ou condição respiratória que responde ao antagonismo m3 - Google Patents

combinação, produto, kit de partes, embalagem, usos de um antagonista de receptores muscarìnicos m3, e de um corticosteróide, e, método de tratar um paciente humano ou animal sofrendo de ou suscetìvel a uma doença ou condição respiratória que responde ao antagonismo m3

Info

Publication number
BRPI0511667A
BRPI0511667A BRPI0511667-8A BRPI0511667A BRPI0511667A BR PI0511667 A BRPI0511667 A BR PI0511667A BR PI0511667 A BRPI0511667 A BR PI0511667A BR PI0511667 A BRPI0511667 A BR PI0511667A
Authority
BR
Brazil
Prior art keywords
corticosteroid
combination
receptor antagonist
packaging
treating
Prior art date
Application number
BRPI0511667-8A
Other languages
English (en)
Inventor
Jordi Gras Escardo
Jesus Llenas Calvo
Hamish Ryder
Pio Orviz Diaz
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34956036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0511667(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of BRPI0511667A publication Critical patent/BRPI0511667A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Wrappers (AREA)

Abstract

COMBINAçãO, PRODUTO, KIT DE PARTES, EMBALAGEM, USOS DE UM ANTAGONISTA DE RECEPTORES MUSCARìNICOS M3, E DE UM CORTICOSTERóIDE, E, MéTODO DE TRATAR UM PACIENTE HUMANO OU ANIMAL SOFRENDO DE OU SUSCETìVEL A UMA DOENçA OU CONDIçãO RESPIRATóRIA QUE RESPONDE AO ANTAGONISMO M3 Um combinação que compreende (a) um corticosteróide e (b) um antagonista de receptores muscarínicos M3 que é (3R)-1-fenetil-3-(9H-xanteno-9-carbonil-óxi)-1-azoniabiciclo¢2.2.2!oct ano, na forma de um sal possuindo um ânion X, que é um ânion farmaceuticamente aceitável de um ácido mono ou polivalente.
BRPI0511667-8A 2004-05-31 2005-05-31 combinação, produto, kit de partes, embalagem, usos de um antagonista de receptores muscarìnicos m3, e de um corticosteróide, e, método de tratar um paciente humano ou animal sofrendo de ou suscetìvel a uma doença ou condição respiratória que responde ao antagonismo m3 BRPI0511667A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200401312A ES2257152B1 (es) 2004-05-31 2004-05-31 Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
PCT/EP2005/005836 WO2005115462A1 (en) 2004-05-31 2005-05-31 Combinations comprising antimuscarinic agents and pde4 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0511667A true BRPI0511667A (pt) 2008-01-02

Family

ID=34956036

Family Applications (6)

Application Number Title Priority Date Filing Date
BRPI0511662A BRPI0511662B8 (pt) 2004-05-31 2005-05-31 combinação e usos de um antagonista de receptores muscarínicos m3 e de um agonista beta2 no tratamento de distúrbios respiratórios
BRPI0511656-2A BRPI0511656A (pt) 2004-05-31 2005-05-31 combinação, produto, kit de partes, embalagem, usos de um antagonista dos receptores muscarìnicos m3 e de um inibidor de pde4, e, método para tratar um paciente sofrendo de ou susceptìvel a uma doença ou condição respiratória que responda ao antagonismo de m3
BRPI0511669-4A BRPI0511669A (pt) 2004-05-31 2005-05-31 combinação, produto, kit de partes, embalagem, usos de um antagonista de receptores muscarìnicos m3, e de um inibidor de pde4, e, método de tratar um paciente sofrendo de ou suscetìvel a uma doença ou condição respiratória que responde ao antagonismo m3
BRPI0511666-0A BRPI0511666A (pt) 2004-05-31 2005-05-31 combinação, produto, kit de partes, embalagem, usos de um antagonista dos receptores muscarìnicos m3 e de um corticosteróide, e, método para tratar um paciente humano ou animal sofrendo de ou susceptìvel a uma doença ou condição respiratória que responda ao antagonismo de m3
BRPI0511660-0A BRPI0511660A (pt) 2004-05-31 2005-05-31 combinação, produto, kit de partes, embalagem, uso de um antagonista de receptores muscarìnicos m3 e de um agonista beta2, e, método para tratar um paciente sofrendo de ou suscetìvel a uma doença ou condição respiratória que responde ao antagonismo m3
BRPI0511667-8A BRPI0511667A (pt) 2004-05-31 2005-05-31 combinação, produto, kit de partes, embalagem, usos de um antagonista de receptores muscarìnicos m3, e de um corticosteróide, e, método de tratar um paciente humano ou animal sofrendo de ou suscetìvel a uma doença ou condição respiratória que responde ao antagonismo m3

Family Applications Before (5)

Application Number Title Priority Date Filing Date
BRPI0511662A BRPI0511662B8 (pt) 2004-05-31 2005-05-31 combinação e usos de um antagonista de receptores muscarínicos m3 e de um agonista beta2 no tratamento de distúrbios respiratórios
BRPI0511656-2A BRPI0511656A (pt) 2004-05-31 2005-05-31 combinação, produto, kit de partes, embalagem, usos de um antagonista dos receptores muscarìnicos m3 e de um inibidor de pde4, e, método para tratar um paciente sofrendo de ou susceptìvel a uma doença ou condição respiratória que responda ao antagonismo de m3
BRPI0511669-4A BRPI0511669A (pt) 2004-05-31 2005-05-31 combinação, produto, kit de partes, embalagem, usos de um antagonista de receptores muscarìnicos m3, e de um inibidor de pde4, e, método de tratar um paciente sofrendo de ou suscetìvel a uma doença ou condição respiratória que responde ao antagonismo m3
BRPI0511666-0A BRPI0511666A (pt) 2004-05-31 2005-05-31 combinação, produto, kit de partes, embalagem, usos de um antagonista dos receptores muscarìnicos m3 e de um corticosteróide, e, método para tratar um paciente humano ou animal sofrendo de ou susceptìvel a uma doença ou condição respiratória que responda ao antagonismo de m3
BRPI0511660-0A BRPI0511660A (pt) 2004-05-31 2005-05-31 combinação, produto, kit de partes, embalagem, uso de um antagonista de receptores muscarìnicos m3 e de um agonista beta2, e, método para tratar um paciente sofrendo de ou suscetìvel a uma doença ou condição respiratória que responde ao antagonismo m3

Country Status (45)

Country Link
US (41) US20050288266A1 (pt)
EP (14) EP2774623B1 (pt)
JP (8) JP4928258B2 (pt)
KR (3) KR101256417B1 (pt)
CN (8) CN1960761A (pt)
AR (1) AR049066A1 (pt)
AT (3) ATE424847T1 (pt)
AU (3) AU2005247103B2 (pt)
BE (1) BE1016608A5 (pt)
BR (6) BRPI0511662B8 (pt)
CA (3) CA2569077C (pt)
CH (1) CH696962A5 (pt)
CL (1) CL2011000607A1 (pt)
CY (7) CY1108885T1 (pt)
DE (3) DE602005013220D1 (pt)
DK (5) DK1763368T4 (pt)
EC (6) ECSP067034A (pt)
ES (7) ES2257152B1 (pt)
FR (2) FR2870744B1 (pt)
GB (1) GB2419819B (pt)
GR (1) GR1006045B (pt)
HR (4) HRP20090215T4 (pt)
HU (2) HUP0600139A3 (pt)
IL (3) IL179687A (pt)
IT (1) ITMI20051021A1 (pt)
LT (1) LTC1763368I2 (pt)
LU (1) LU91214B1 (pt)
MC (1) MC200083A1 (pt)
ME (4) ME02134B (pt)
MX (3) MXPA06013848A (pt)
MY (1) MY142095A (pt)
NL (2) NL1029151C2 (pt)
NO (7) NO20065483L (pt)
NZ (3) NZ544539A (pt)
PE (3) PE20060292A1 (pt)
PL (6) PL1765404T3 (pt)
PT (4) PT1763369E (pt)
RS (4) RS51386B (pt)
RU (4) RU2404771C3 (pt)
SI (5) SI1763369T1 (pt)
TW (1) TWI404530B (pt)
UA (6) UA89183C2 (pt)
UY (1) UY28933A1 (pt)
WO (3) WO2005115462A1 (pt)
ZA (6) ZA200600261B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100471016B1 (ko) * 1996-08-07 2005-07-12 스미또모 가가꾸 가부시키가이샤 살충성에어로졸조성물및이를제조하기위한살충조성물
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
MXPA06001046A (es) * 2003-07-29 2006-04-24 Boehringer Ingelheim Int Combinacion de un anticolinergico y un esteroide y su uso para tratar trastornos respiratorios por inhalacion.
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
NZ551669A (en) * 2004-05-31 2010-07-30 Almirall Lab Combinations comprising antimuscarinic agents and PDE4 inhibitors
EP1859804B1 (en) * 2005-02-10 2016-12-07 Oncolys BioPharma, Inc. Anticancer agent combination therapy
WO2007071313A2 (en) * 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
CA2643130A1 (en) * 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compounds and methods of treating disorders associated with activation of metachromatic cells
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
TWI436761B (zh) * 2006-06-19 2014-05-11 Otsuka Pharma Co Ltd 使用噻唑衍生物之方法
ES2378281T3 (es) * 2006-07-05 2012-04-10 Nycomed Gmbh Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias
TW200821316A (en) 2006-07-19 2008-05-16 Astrazeneca Ab Novel compounds 243
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
BRPI0806392A8 (pt) * 2007-02-21 2019-10-01 Almirall Sa uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2011513203A (ja) * 2008-03-14 2011-04-28 大塚製薬株式会社 Ｍｍｐ−２及び／又はｍｍｐ−９阻害剤
CN102105448B (zh) 2008-05-27 2013-11-13 阿斯利康(瑞典)有限公司 苯氧基吡啶基酰胺衍生物和它们在治疗由pde4介导的病症中的用途
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP2156847A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor.
JP5809985B2 (ja) 2009-02-26 2015-11-11 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
NZ606548A (en) 2010-08-03 2015-02-27 Chiesi Farma Spa Dry powder formulation comprising a phosphodiesterase inhibitor
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
HRP20151317T1 (hr) 2011-06-10 2016-01-01 Chiesi Farmaceutici S.P.A. Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
RU2606121C2 (ru) 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
MX368199B (es) * 2012-01-25 2019-09-24 Chiesi Farm Spa Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación.
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US9156833B2 (en) 2012-07-16 2015-10-13 Barry University, Inc. Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
EP3345904B1 (en) 2012-12-06 2020-07-29 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR102156441B1 (ko) 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
SI2968313T1 (en) 2013-03-15 2018-05-31 Verona Pharma Plc Combination of medicines
EP3055438B1 (en) * 2013-10-09 2023-03-15 MiRus LLC A method of forming a medical device and a medical device in the form of an orthodontics device
JP6527145B2 (ja) 2013-11-15 2019-06-05 ローディア オペレーションズ 金属コーティング用のポリアミド組成物およびそれでコートされた金属部材
AU2015204531B2 (en) * 2014-01-10 2019-11-14 Afimmune Limited Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR102794286B1 (ko) * 2016-01-08 2025-04-09 테론 파마슈티칼즈, 인크. 7-아조니아바이사이클로[2.2.1]헵탄 유도체의 건조 분말 흡입기 조성물
EP3484879B1 (en) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US11065235B2 (en) 2017-05-19 2021-07-20 Council Of Scientific & Industrial Research Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof
US12582809B2 (en) 2018-01-26 2026-03-24 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor
IL281809B (en) 2018-09-28 2022-09-01 Karuna Therapeutics Inc Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
IT202000006442A1 (it) * 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11504332B2 (en) * 2021-03-23 2022-11-22 Vk Research Associates Inc. Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof
EP4404924A4 (en) * 2021-09-23 2025-08-13 Curasen Therapeutics Inc BETA-ADRENERGIC AGONIST AND METHODS OF USE THEREOF

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) * 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
FR2539135B1 (fr) * 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4843074A (en) * 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) * 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) * 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
US5507281A (en) * 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
DE69129188T2 (de) 1990-09-26 1998-07-30 Pharmachemie B.V., Haarlem Inhalator mit einem reservoir für mehrere dosierte inhalationsmittel, mit transportvorrichtung und mit wirbelkammer
GB9026025D0 (en) * 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
DE4239402A1 (de) * 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
EP0673240B1 (en) * 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilized medicinal aerosol solution formulations
CA2152088C (en) 1992-12-18 1999-12-07 Thomas J. Ambrosio Inhaler for powdered medications
GB9412434D0 (en) * 1994-06-21 1994-08-10 Inmos Ltd Computer instruction compression
JPH11509434A (ja) 1995-04-14 1999-08-24 グラクソ、ウェルカム、インコーポレーテッド サルメテロール用計量投与用吸入器
JP3299971B2 (ja) 1995-06-21 2002-07-08 アスタ メディカ アクチエンゲゼルシャフト 一体的に形成された調量装置を備えた薬用粉末カートリッジおよび粉末薬剤吸入器
DE19528145A1 (de) * 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) * 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
ITMI981671A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) * 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
DE60125026T2 (de) * 2000-03-23 2007-06-28 Takeda Pharmaceutical Co. Ltd. Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
WO2002000241A2 (en) * 2000-06-28 2002-01-03 Aventis Pharma S.A. Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
US6706726B2 (en) * 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
US6852728B2 (en) * 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20020122773A1 (en) * 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
AU2002210575A1 (en) 2000-10-31 2002-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicament compositions based on anticholinergics and corticosteroids
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
CN1250545C (zh) * 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
US20020179087A1 (en) * 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
ES2276942T3 (es) * 2001-05-25 2007-07-01 BOEHRINGER INGELHEIM PHARMA GMBH &amp; CO.KG Combinacion de un inhibidor de pde4 y tiotropio o un derivado del mismo para tratar vias respiratorias obstructivas y otras enfermedades inflamatorias.
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
US6974803B2 (en) * 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
US6790856B2 (en) * 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US6756508B2 (en) * 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
US7094788B2 (en) * 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
BR0310084A (pt) * 2002-05-17 2005-02-15 Novartis Ag Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
KR20060011783A (ko) * 2002-06-12 2006-02-03 에피제네시스 파마슈티칼스 아이엔씨 데하이드로에피안드로스테론 스테로이드 및항-무스카린제와 더불어 호흡기 및 폐 질환을 치료하기위한 조성물, 제제 및 키트
NZ537584A (en) * 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
WO2004039968A1 (ja) * 2002-10-30 2004-05-13 Japan Science And Technology Agency 骨髄由来の不死化樹状細胞株
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
CA2506949A1 (en) * 2002-11-27 2004-06-10 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) * 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
CA2519682A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
ATE384529T1 (de) * 2003-03-28 2008-02-15 Nycomed Gmbh Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
DE602004005462T2 (de) * 2003-07-29 2007-07-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medikamente zur inhalation mit betamimetika und einem anticholinergikum
US20050026886A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
JP2007500676A (ja) * 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2005210085B2 (en) * 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
PL1713471T3 (pl) * 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
DK1718336T3 (da) * 2004-02-06 2008-10-20 Meda Pharma Gmbh & Co Kg Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
US7375935B2 (en) * 2004-04-12 2008-05-20 Leviton Manufacturing Co., Inc. Ground fault circuit interrupter with enhanced radio frequency interference suppression
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens

Also Published As

Publication number Publication date
US20120040943A1 (en) 2012-02-16
FR2870744A1 (fr) 2005-12-02
PL2292267T3 (pl) 2015-03-31
EP2774623A1 (en) 2014-09-10
HK1095757A1 (en) 2007-05-18
ME02779B (me) 2010-06-30
NZ544539A (en) 2007-09-28
RS53529B1 (sr) 2015-02-27
US20200009117A1 (en) 2020-01-09
NO20065476L (no) 2006-12-28
HRP20090215T1 (en) 2009-05-31
DK1763368T4 (da) 2013-11-04
NL1029151C2 (nl) 2006-06-22
DK2292267T3 (da) 2014-09-15
RU2404771C2 (ru) 2010-11-27
ATE474600T1 (de) 2010-08-15
BRPI0511666A (pt) 2008-01-02
US20150080359A1 (en) 2015-03-19
RU2465902C2 (ru) 2012-11-10
AR049066A1 (es) 2006-06-21
UA89184C2 (ru) 2010-01-11
US20120309727A1 (en) 2012-12-06
RU2373935C2 (ru) 2009-11-27
EP2002845A2 (en) 2008-12-17
CN1972716A (zh) 2007-05-30
DE602005013220D1 (de) 2009-04-23
BRPI0511660A (pt) 2008-01-02
JP5133054B2 (ja) 2013-01-30
HK1198120A1 (en) 2015-03-13
ITMI20051021A1 (it) 2005-12-01
SI21784A (sl) 2005-12-31
US20130252928A1 (en) 2013-09-26
AU2005247107A1 (en) 2005-12-08
CY1108902T1 (el) 2014-07-02
RU2010129940A (ru) 2012-01-27
NO2015007I2 (no) 2015-12-21
DK1763368T3 (da) 2009-05-04
JP4928258B2 (ja) 2012-05-09
ECSP067037A (es) 2006-12-29
AU2005247103B2 (en) 2010-10-28
EP1761280A1 (en) 2007-03-14
HUP0600139A3 (en) 2010-12-28
NL300720I2 (pt) 2016-01-07
NO2015007I1 (no) 2015-03-09
US20140296197A1 (en) 2014-10-02
KR20070024556A (ko) 2007-03-02
JP5049120B2 (ja) 2012-10-17
SI1763368T1 (sl) 2009-08-31
PL1763368T3 (pl) 2009-08-31
EP2319538A2 (en) 2011-05-11
NO334337B1 (no) 2014-02-10
US20080146603A1 (en) 2008-06-19
US20090093503A1 (en) 2009-04-09
DK1891973T3 (da) 2010-10-18
US20130035319A1 (en) 2013-02-07
US20060154934A1 (en) 2006-07-13
BRPI0511662B1 (pt) 2019-02-19
CY1110798T1 (el) 2015-06-10
EP1763369A1 (en) 2007-03-21
HRP20090107T3 (en) 2009-03-31
MXPA06013847A (es) 2007-03-01
UA89182C2 (ru) 2010-01-11
AU2005247103A1 (en) 2005-12-08
US20150202213A1 (en) 2015-07-23
US20110021478A1 (en) 2011-01-27
ME01670B (me) 2010-06-30
SI1763368T2 (sl) 2013-12-31
AU2005247108B2 (en) 2008-09-11
US20120059031A1 (en) 2012-03-08
KR20130027586A (ko) 2013-03-15
NO20065483L (no) 2006-12-22
ZA200609990B (en) 2007-12-27
IL179689A0 (en) 2007-05-15
EP2002844B1 (en) 2010-12-29
ZA200609986B (en) 2007-11-28
DE602005011803D1 (de) 2009-01-29
EP2002845A3 (en) 2009-02-25
HK1125573A1 (en) 2009-08-14
PL1891973T3 (pl) 2010-11-30
ES2293849A1 (es) 2008-03-16
ES2348558T3 (es) 2010-12-09
US20170049756A1 (en) 2017-02-23
EP1765404B1 (en) 2008-12-31
CY2015006I1 (el) 2016-06-22
HK1090306A1 (en) 2006-12-22
HUS1500011I1 (hu) 2018-09-28
EP2774622B1 (en) 2015-03-11
SI1763369T1 (sl) 2009-06-30
CN1960759B (zh) 2011-07-13
ES2318498T3 (es) 2009-05-01
NZ551667A (en) 2010-07-30
AU2005247108A1 (en) 2005-12-08
US20100048616A1 (en) 2010-02-25
US20120309726A1 (en) 2012-12-06
PL1765404T3 (pl) 2009-06-30
EP2002844A3 (en) 2009-03-04
EP2002843A2 (en) 2008-12-17
MXPA06004124A (es) 2006-06-27
US20140148420A1 (en) 2014-05-29
JP2012184272A (ja) 2012-09-27
ME02134B (me) 2015-02-27
US20050288266A1 (en) 2005-12-29
ZA200609989B (en) 2007-11-28
IL179687A (en) 2011-11-30
JP2008500990A (ja) 2008-01-17
US20140094442A1 (en) 2014-04-03
ECSP067034A (es) 2006-12-29
NO338621B1 (no) 2016-09-19
CN1960759A (zh) 2007-05-09
US20090111785A1 (en) 2009-04-30
ZA200609987B (en) 2007-12-27
CA2569077C (en) 2012-12-18
PT1891973E (pt) 2010-09-27
BE1016608A5 (fr) 2007-02-06
BRPI0511662A (pt) 2008-01-02
PE20081649A1 (es) 2008-11-28
ES2505329T3 (es) 2014-10-09
EP2002844A2 (en) 2008-12-17
ES2257152B1 (es) 2007-07-01
BRPI0511656A (pt) 2008-01-02
CA2533061C (en) 2008-07-08
CY1109938T1 (el) 2014-09-10
CN102085373A (zh) 2011-06-08
MXPA06013848A (es) 2007-03-01
FR15C0017I2 (fr) 2015-11-13
SI2292267T1 (sl) 2014-11-28
EP2292267B1 (en) 2014-07-23
US20050267078A1 (en) 2005-12-01
UA86976C2 (ru) 2009-06-10
US20110021476A1 (en) 2011-01-27
ES2322280T5 (es) 2013-12-03
LU91214B1 (fr) 2006-01-26
RS50717B (sr) 2010-06-30
SI1891973T1 (sl) 2010-11-30
JP2008500987A (ja) 2008-01-17
RS50787B2 (sr) 2018-02-28
PE20060292A1 (es) 2006-04-14
NO20065477L (no) 2006-12-22
UA89183C2 (ru) 2010-01-11
WO2005115466A8 (en) 2007-01-04
TW200608971A (en) 2006-03-16
MC200083A1 (fr) 2005-12-07
CA2569077A1 (en) 2005-12-08
EP1763368A1 (en) 2007-03-21
JP5538485B2 (ja) 2014-07-02
US20070232637A1 (en) 2007-10-04
JP5032984B2 (ja) 2012-09-26
CH696962A5 (fr) 2008-02-29
US20100056486A1 (en) 2010-03-04
WO2005115467A1 (en) 2005-12-08
US20080045565A1 (en) 2008-02-21
NO20065482L (no) 2006-12-22
US20180200234A1 (en) 2018-07-19
CY2015006I2 (el) 2016-06-22
JP2012012407A (ja) 2012-01-19
NO20065479L (no) 2006-12-22
EP2319538A3 (en) 2011-06-15
US20100048615A1 (en) 2010-02-25
CN102755321A (zh) 2012-10-31
CA2568566A1 (en) 2005-12-08
IL179684A (en) 2011-11-30
EP1765404A1 (en) 2007-03-28
CN101018566A (zh) 2007-08-15
US20070167489A1 (en) 2007-07-19
US20060189651A1 (en) 2006-08-24
EP2774623B1 (en) 2015-04-08
US20150306079A1 (en) 2015-10-29
EP1763368B2 (en) 2013-08-21
US20050267135A1 (en) 2005-12-01
US20120302532A1 (en) 2012-11-29
GB2419819A (en) 2006-05-10
HRP20140864T1 (hr) 2014-12-05
CY1108885T1 (el) 2014-07-02
GB2419819B (en) 2007-02-21
CY1109139T1 (el) 2014-07-02
ES2348680T3 (es) 2010-12-10
EP1763368B1 (en) 2009-03-11
RU2006147250A (ru) 2008-07-20
EP1891973B1 (en) 2010-07-21
HRP20100489T1 (hr) 2010-10-31
EP2138188A1 (en) 2009-12-30
WO2005115462A1 (en) 2005-12-08
BRPI0511669A (pt) 2008-01-02
KR101174677B1 (ko) 2012-08-17
NZ551668A (en) 2010-06-25
RS50787B (sr) 2010-08-31
PL1763369T3 (pl) 2009-06-30
PT1763369E (pt) 2009-02-26
RU2006142331A (ru) 2008-06-20
DE602005022497D1 (de) 2010-09-02
ZA200600261B (en) 2007-04-25
PT2292267E (pt) 2014-10-15
FR2870744B1 (fr) 2006-12-08
ECSP067036A (es) 2006-12-29
ATE424847T1 (de) 2009-03-15
JP2008500989A (ja) 2008-01-17
ES2257152A1 (es) 2006-07-16
AU2005247107B2 (en) 2010-10-28
TWI404530B (zh) 2013-08-11
WO2005115466A1 (en) 2005-12-08
ZA200609985B (en) 2008-09-25
ES2293849B2 (es) 2009-04-16
PE20081650A1 (es) 2008-12-06
US20160038470A1 (en) 2016-02-11
CA2568566C (en) 2012-12-18
PL379660A1 (pl) 2006-11-13
CA2533061A1 (en) 2005-12-08
RS51386B (sr) 2011-02-28
ECSP067033A (es) 2006-12-29
BRPI0511662B8 (pt) 2021-05-25
EP2002843A3 (en) 2009-04-08
ES2322280T3 (es) 2009-06-18
DK1765404T3 (da) 2009-03-16
CN1960761A (zh) 2007-05-09
GB0526502D0 (en) 2006-02-08
US20080051378A1 (en) 2008-02-28
JP2008500988A (ja) 2008-01-17
US20090099148A1 (en) 2009-04-16
JP4966192B2 (ja) 2012-07-04
RU2006147268A (ru) 2008-07-20
ECSP067038A (es) 2006-12-29
EP2210613A1 (en) 2010-07-28
FR15C0017I1 (pt) 2015-03-04
IE20050366A1 (en) 2005-11-30
UY28933A1 (es) 2005-08-31
JP2008500986A (ja) 2008-01-17
PL1763368T5 (pl) 2014-01-31
US20090176751A1 (en) 2009-07-09
KR20070018105A (ko) 2007-02-13
CY1115669T1 (el) 2017-01-25
JP2006527183A (ja) 2006-11-30
HUP0600139A2 (en) 2007-06-28
NL300720I1 (pt) 2016-01-07
DK1763369T3 (da) 2009-03-16
US20130310354A1 (en) 2013-11-21
EP2774622A1 (en) 2014-09-10
US20120088743A1 (en) 2012-04-12
US20110021477A1 (en) 2011-01-27
UA89181C2 (ru) 2010-01-11
US20120071452A1 (en) 2012-03-22
CN102755321B (zh) 2015-07-15
ME01680B (me) 2010-08-31
ATE417627T1 (de) 2009-01-15
ECSP067035A (es) 2006-12-29
EP1891973A1 (en) 2008-02-27
KR101256417B1 (ko) 2013-04-22
GR20050100269A (el) 2005-12-31
RU2385721C2 (ru) 2010-04-10
UA89185C2 (ru) 2010-01-11
NL1029151A1 (nl) 2005-12-05
MY142095A (en) 2010-09-15
EP2292267A3 (en) 2011-06-15
HRP20090215T4 (hr) 2013-12-20
CN1960762A (zh) 2007-05-09
EP1763369B1 (en) 2008-12-17
NO20065478L (no) 2006-12-28
RU2404771C3 (ru) 2018-03-12
IL179684A0 (en) 2007-05-15
JP5107701B2 (ja) 2012-12-26
IL179689A (en) 2012-02-29
LTC1763368I2 (lt) 2016-12-27
US20060205702A1 (en) 2006-09-14
EP2292267A2 (en) 2011-03-09
IL179687A0 (en) 2007-05-15
GR1006045B (el) 2008-09-08
CL2011000607A1 (es) 2011-08-19
PT1763368E (pt) 2009-05-14
CN1960760A (zh) 2007-05-09

Similar Documents

Publication Publication Date Title
BRPI0511666A (pt) combinação, produto, kit de partes, embalagem, usos de um antagonista dos receptores muscarìnicos m3 e de um corticosteróide, e, método para tratar um paciente humano ou animal sofrendo de ou susceptìvel a uma doença ou condição respiratória que responda ao antagonismo de m3
JP6673924B2 (ja) 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
EP2120938A4 (en) IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
BR112015019720A2 (pt) inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c
CA2883751A1 (en) Methods of treating alzheimer&#39;s disease and pharmaceutical compositions thereof
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BRPI0517494A (pt) composto, composição farmacêutica, método de ativação/estimulação seletiva de receptores nicotìnicos de a-7 em um paciente em que tal ativação/estimulação tem um efeito terapêutico, método de tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de debilitação da memória e/ou da cognição, método de tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método de tratamento de um paciente que sofre de debilitação da memória devido à debilitação cognitiva suave devido ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do snc, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método de tratamento e/ou prevenção da demência em um paciente com o mal de alzheimer, método de tratamento de um paciente para cortar o vìcio do álcool ou o tratamento de um paciente com a terapia anti-intoxicação, método de tratamento de um paciente para propiciar neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamatos, método de tratamento de um paciente que sofre do vìcio da nicotina, dor, tontura do fuso horário, obesidade e/ou diabetes, método de indução do ato de parar fumar em um paciente, método de tratamento de um paciente que sofre de debilitação cognitiva suave (mci), demência vascular (vad), declìnio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia com o coração aberto, parada cardìaca, anestesia geral, deficiências da memória devido à exposição a agentes anestésicos, debilitação cognitiva induzida pela privação do sono, sìndrome de fadiga crÈnica, narcolepsia, demência relacionada com a aids, debilitação cognitiva relacionada com a epilepsia, sìndrome de down, demência relacionada ao alcoolismo, debilitações da memória induzidas por drogas/substáncias, demência pugilìstica (sìndrome do boxeador), ou demência animal, método para o tratamento da perda da memória, método para o tratamento de um paciente que sofre de debilitação da memória, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da disfunção da transmissão do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante de receptores nicotìnicos de acetilcolina defeituosos ou funcionando mal em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da transmissão suprimida do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da perda de sinapses colinérgicas em um paciente, método para a proteção dos neurÈnios em um paciente com neurotoxicidade induzi
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
AR095197A1 (es) Combinación de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cáncer pulmonar de células no pequeñas
PE20110711A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma
BRPI0412382A (pt) composto , método para a verificação de novos compostos medicinais que se ligam a e modulam a atividade, por agonismo , agonismo parcial, ou antagonismo, do receptor de acetilcolina nicotìnico alfa7, método de tratamento ou profilaxia de uma doença ou condição humana, método para tratamento de jetlag, induzindo interrupção de fumar, vìcio em nicotina, abstinência, dor, e para colite ulcerativa, composição farmacêutica, e, método de tratamento ou prevenção de uma condição ou distúrbio que surge da disfunção de neurotransmissão do receptor de acetilcolina nicotìnico em um mamìfero, e, uso de um composto
BR112014030099A2 (pt) combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor
BRPI0407097A (pt) Antagonista do casr
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
MA37742B1 (fr) Dérivés d&#39;oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
BR112012016783A2 (pt) &#34;usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia&#34;
MA38425A1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
BR112015020140A8 (pt) ácido 1-{4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil}-azetidina-3-carboxílico, seus usos e combinação farmacêutica
EA036542B9 (ru) Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
AR059864A1 (es) Compuesto de benzamida composicion farmaceutica que lo comprende su uso para preparar un medicamento y procedimientos para su preparacion
BR112014005538A2 (pt) composições aquosas compreendendo arbecacina
BR0208941A (pt) Novos antagonistas receptores de ocitocina tocolìticos de hidróxi ciclohexenil fenil carboxamidas

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: LABORATORIOS ALMIRALL, S.A. (ES)

Free format text: ALTERADO DE: ALMIRALL PRODESFARMA, S.A.

B25D Requested change of name of applicant approved

Owner name: ALMIRALL, S.A. (ES)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2437 DE 19/09/2017 POR TER SIDO INDEVIDA.